zoledronic acid has been researched along with pyrazines in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (30.00) | 29.6817 |
| 2010's | 14 (70.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Berenson, JR | 1 |
| Chou, T | 1 |
| McKenna, KE; Morris, TC; Ramadan, KM | 1 |
| Anagnostopoulos, A; Chantry, A; Croucher, PI; Dimopoulos, MA; Heath, DJ; Katodritou, E; Pouli, A; Rahemtulla, A; Terpos, E; Verrou, E; Vervessou, EC; Zervas, K | 1 |
| Bostan, F; Ozkaynak, C; Timurağaoğlu, A; Tuzuner, S; Undar, L | 1 |
| Bamia, C; Bamias, A; Christoulas, D; Dimopoulos, MA; Eleftherakis-Papaiakovou, E; Gika, D; Kastritis, E; Melakopoulos, I; Migkou, M; Roussou, M; Terpos, E | 1 |
| D'Auria, F; Dammacco, F; Di Pietro, G; Ditonno, P; Gnoni, A; Guarini, A; Mangialardi, G; Moschetta, M; Musto, P; Ria, R; Ribatti, D; Ricciardi, MR; Vacca, A | 1 |
| Anargyrou, K; Christoulas, D; Dimopoulos, MA; Gavriatopoulou, M; Kokkoris, P; Migkou, M; Terpos, E; Tsionos, K | 1 |
| Abeltino, M; Agnelli, L; Bolzoni, M; Bonomini, S; Colla, S; Giuliani, N; Neri, A; Rizzoli, V; Storti, P; Todoerti, K | 1 |
| Fukami, K; Koike, K; Morishige, S; Okamura, T; Okuda, S; Taguchi, K; Yakushiji, K | 1 |
| Iida, S | 1 |
| Morgan, G | 1 |
| Locke, FL; Morgan, GJ | 1 |
| Suzuki, K | 1 |
| McCarthy, PL | 1 |
| Collet, P; Marotte, H; Nizeica, V | 1 |
| Baldock, PA; Kostenuik, PJ; Little, DG; McDonald, MM; Mikulec, K; Morse, A; Peacock, L | 1 |
| Bakhous, A; Waheed, S; Zhu, H | 1 |
| Bokhari, SW; Jones, FM | 1 |
| Anderson, KC; Bianchi, G; Richardson, PG | 1 |
6 review(s) available for zoledronic acid and pyrazines
| Article | Year |
|---|---|
Advances in the biology and treatment of myeloma bone disease.
Topics: Bone Resorption; Boronic Acids; Bortezomib; Carrier Proteins; Clinical Trials as Topic; Cytokines; Diphosphonates; Endothelial Growth Factors; Glycoproteins; Humans; Imidazoles; Immunoglobulin Fc Fragments; Intercellular Signaling Peptides and Proteins; Lymphokines; Membrane Glycoproteins; Multiple Myeloma; Osteoprotegerin; Pamidronate; Pyrazines; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; Recombinant Fusion Proteins; Signal Transduction; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors; Zoledronic Acid | 2002 |
[Multiple myeloma--recent advances in diagnosis and treatment].
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Diphosphonates; Dose-Response Relationship, Drug; Hematopoietic Stem Cell Transplantation; Humans; Imidazoles; Multiple Myeloma; Neoplasm Staging; Pamidronate; Protease Inhibitors; Pyrazines; Thalidomide; Zoledronic Acid | 2005 |
[Multiple myeloma].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Denosumab; Diphosphonates; Humans; Imidazoles; Melphalan; Multiple Myeloma; Peripheral Nervous System Diseases; Prednisolone; Pyrazines; Randomized Controlled Trials as Topic; Thalidomide; Zoledronic Acid | 2012 |
What is the evidence for the use of bisphosphonate therapy in newly diagnosed multiple myeloma patients lacking bone disease?
Topics: Bone Diseases; Boronic Acids; Bortezomib; Dexamethasone; Diphosphonates; Fatigue; Fractures, Bone; Humans; Imidazoles; In Situ Hybridization, Fluorescence; Lenalidomide; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Myeloma; Proteinuria; Pyrazines; Randomized Controlled Trials as Topic; Thalidomide; Time Factors; Translocation, Genetic; Treatment Outcome; Zoledronic Acid | 2012 |
Current therapeutic strategy for multiple myeloma.
Topics: Age Factors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone and Bones; Bone Density Conservation Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Creatinine; Cyclophosphamide; Denosumab; Dexamethasone; Diphosphonates; Doxorubicin; Hematopoietic Stem Cell Transplantation; Humans; Imidazoles; Immunoglobulins; Kidney; Lenalidomide; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Melphalan; Molecular Targeted Therapy; Multiple Myeloma; Neoplasms, Second Primary; Precision Medicine; Prednisolone; Pyrazines; Quality of Life; Recurrence; Remission Induction; Survival Rate; Thalidomide; Zoledronic Acid | 2013 |
Part I: the role of maintenance therapy in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantation.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Boronic Acids; Bortezomib; Diphosphonates; Hematopoietic Stem Cell Transplantation; Humans; Imidazoles; Immunologic Factors; Lenalidomide; Maintenance Chemotherapy; Multiple Myeloma; Pyrazines; Thalidomide; Transplantation, Autologous; Zoledronic Acid | 2013 |
14 other study(ies) available for zoledronic acid and pyrazines
| Article | Year |
|---|---|
Clinical response of cutaneous squamous-cell carcinoma to bortezomib given for myeloma.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Clarithromycin; Dexamethasone; Diphosphonates; Glomerulonephritis; Humans; Idarubicin; Imidazoles; Immunosuppressive Agents; Male; Melphalan; Middle Aged; Multiple Myeloma; Nephrotic Syndrome; Pamidronate; Protein Synthesis Inhibitors; Pyrazines; Skin Neoplasms; Thalidomide; Zoledronic Acid | 2006 |
Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma.
Topics: Acid Phosphatase; Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Biomarkers; Bone Remodeling; Boronic Acids; Bortezomib; Case-Control Studies; Collagen Type I; Diphosphonates; Female; Humans; Imidazoles; Intercellular Signaling Peptides and Proteins; Isoenzymes; Male; Middle Aged; Multiple Myeloma; Osteocalcin; Osteoprotegerin; Peptides; Protease Inhibitors; Pyrazines; RANK Ligand; Recurrence; Statistics, Nonparametric; Tartrate-Resistant Acid Phosphatase; Zoledronic Acid | 2006 |
Improvement of zoledronic-acid-induced jaw osteonecrosis with bortezomib.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Diphosphonates; Doxorubicin; Female; Humans; Imidazoles; Mandibular Diseases; Middle Aged; Multiple Myeloma; Osteonecrosis; Peripheral Blood Stem Cell Transplantation; Postoperative Complications; Protease Inhibitors; Pyrazines; Tooth Extraction; Transplantation, Autologous; Vincristine; Zoledronic Acid | 2007 |
Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Density Conservation Agents; Boronic Acids; Bortezomib; Dental Prophylaxis; Diphosphonates; Female; Humans; Imidazoles; Incidence; Jaw Diseases; Male; Middle Aged; Multiple Myeloma; Osteonecrosis; Pyrazines; Retrospective Studies; Thalidomide; Young Adult; Zoledronic Acid | 2009 |
Bortezomib and zoledronic acid on angiogenic and vasculogenic activities of bone marrow macrophages in patients with multiple myeloma.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Boronic Acids; Bortezomib; Cell Adhesion; Cell Movement; Cell Proliferation; Diphosphonates; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Imidazoles; Macrophages; Male; Middle Aged; Multiple Myeloma; Neovascularization, Pathologic; NF-kappa B; Phosphorylation; Pyrazines; Vascular Endothelial Growth Factor Receptor-2; Zoledronic Acid | 2010 |
Increased bone mineral density in a subset of patients with relapsed multiple myeloma who received the combination of bortezomib, dexamethasone and zoledronic acid.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Density; Bone Density Conservation Agents; Boronic Acids; Bortezomib; Dexamethasone; Diphosphonates; Drug Therapy, Combination; Female; Humans; Imidazoles; Male; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Survival Rate; Treatment Outcome; Zoledronic Acid | 2010 |
The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide.
Topics: Aged; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Cell Proliferation; Diphosphonates; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Humans; Imidazoles; Middle Aged; Multiple Myeloma; Oxides; Polymerase Chain Reaction; Pyrazines; Zoledronic Acid | 2011 |
[Case report; a case of acute kidney injury due to intravenous zoledronic acid hydrate, improved with bortezomib plus dexamethazone therapy in a patient with multiple myeloma].
Topics: Acute Kidney Injury; Adult; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Boronic Acids; Bortezomib; Dexamethasone; Diphosphonates; Drug Therapy, Combination; Humans; Imidazoles; Injections, Intravenous; Male; Multiple Myeloma; Pyrazines; Zoledronic Acid | 2011 |
Myeloma: diagnosis complications and supportive care.
Topics: Amyloidosis; Anemia; Antineoplastic Agents; Bone Density Conservation Agents; Bone Diseases; Boronic Acids; Bortezomib; Diphosphonates; Humans; Imidazoles; Multiple Myeloma; Pyrazines; Quality of Life; Renal Insufficiency; Thrombosis; Zoledronic Acid | 2012 |
Bortezomib induced a phrenic palsy in a multiple myeloma patient.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Boronic Acids; Bortezomib; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Diagnosis, Differential; Diphosphonates; gamma-Aminobutyric Acid; Humans; Imidazoles; Male; Melphalan; Multiple Myeloma; Nerve Compression Syndromes; Neuralgia; Phrenic Nerve; Prednisone; Pregabalin; Protease Inhibitors; Pyrazines; Respiratory Paralysis; Zoledronic Acid | 2013 |
Matrix metalloproteinase-driven endochondral fracture union proceeds independently of osteoclast activity.
Topics: Animals; Bone Density Conservation Agents; Clodronic Acid; Collagenases; Diphosphonates; Femoral Fractures; Fracture Healing; Humans; Hydroxamic Acids; Imidazoles; Male; Matrix Metalloproteinase Inhibitors; Osteoclasts; Osteoprotegerin; Pyrazines; Rats; Rats, Wistar; Recombinant Proteins; Sulfonamides; Time Factors; Zoledronic Acid | 2013 |
Waldeström macroglobulinaemia relapsing with focal bone disease and achieving major response with single-agent zoledronic acid.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Resorption; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Diphosphonates; Hematopoietic Stem Cell Transplantation; Humans; Imidazoles; Male; Melphalan; Middle Aged; Multimodal Imaging; Osteolysis; Positron-Emission Tomography; Pyrazines; Recurrence; Remission Induction; Rituximab; Tomography, X-Ray Computed; Waldenstrom Macroglobulinemia; Zoledronic Acid | 2013 |
Hyperammonemic encephalopathy in multiple myeloma.
Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Back Pain; Boronic Acids; Bortezomib; Brain; Brain Edema; Coma; Cyclophosphamide; Dexamethasone; Diphosphonates; Fatal Outcome; Humans; Hyperammonemia; Imidazoles; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Myeloma; Osteolysis; Pyrazines; Tomography, X-Ray Computed; Zoledronic Acid | 2014 |
Best treatment strategies in high-risk multiple myeloma: navigating a gray area.
Topics: Antineoplastic Combined Chemotherapy Protocols; Back Pain; Biopsy; Bone Density Conservation Agents; Bone Marrow; Boronic Acids; Bortezomib; Dexamethasone; Diphosphonates; Fatigue; Hematopoietic Stem Cell Transplantation; Humans; Imidazoles; Immunoglobulin G; Immunoglobulin lambda-Chains; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Pyrazines; Referral and Consultation; Thalidomide; Translocation, Genetic; Transplantation, Autologous; Zoledronic Acid | 2014 |